Processa Pharmaceuticals Inc (PCSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -13,564 | -11,850 | -11,122 | -27,424 | -11,428 |
| Depreciation Amortization | 1 | 1 | 0 | 904 | 791 |
| Income taxes - deferred | N/A | N/A | N/A | N/A | -531 |
| Accounts payable and accrued liabilities | 176 | 569 | -16 | 109 | -102 |
| Other Working Capital | 1,544 | -112 | 605 | 544 | -1,179 |
| Other Operating Activity | 457 | 147 | 2,469 | 16,263 | 3,730 |
| Operating Cash Flow | $-11,385 | $-11,245 | $-8,063 | $-9,605 | $-8,717 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | -3 | N/A | N/A |
| Purchase Sale Intangibles | -850 | N/A | N/A | N/A | N/A |
| Other Investing Activity | -850 | -3 | 0 | 0 | 0 |
| Investing Cash Flow | $-850 | $-3 | $-3 | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 16,598 | 7,763 | 6,322 | N/A | 10,050 |
| Common Stock Repurchased | N/A | N/A | N/A | -300 | N/A |
| Other Financing Activity | -17 | -30 | -53 | -89 | -251 |
| Financing Cash Flow | $16,581 | $7,733 | $6,269 | $-389 | $9,799 |
| Beginning Cash Position | 1,191 | 4,706 | 6,504 | 16,498 | 15,416 |
| End Cash Position | 5,537 | 1,191 | 4,706 | 6,504 | 16,498 |
| Net Cash Flow | $4,346 | $-3,515 | $-1,797 | $-9,994 | $1,081 |
| Free Cash Flow | |||||
| Operating Cash Flow | -11,385 | -11,245 | -8,063 | -9,605 | -8,717 |
| Capital Expenditure | N/A | N/A | -3 | N/A | N/A |
| Free Cash Flow | -11,385 | -11,245 | -8,066 | -9,605 | -8,717 |